Group 1 - The core theme of the conference is "Source Without Boundaries," focusing on the innovative ecosystem and industrial strength in advanced therapies in Zhangjiang [1] - Since 2019, Pudong has approved 29 Class 1 new drugs, accounting for 78% of Shanghai's total, and 31 innovative medical devices, accounting for 57% of Shanghai's total [1] - In 2023, Pudong has seen the approval of 6 Class 1 innovative drugs and 4 innovative medical devices, covering multiple major disease areas with several "first" and "first-of-its-kind" breakthroughs [1] Group 2 - Pudong has gathered over 170 upstream and downstream enterprises in the cell and gene therapy field, achieving significant breakthroughs in first and first-of-its-kind cell gene drugs [1] - The Shanghai Zhangjiang Group aims to enhance the brand influence of Zhangjiang Medicine Valley by unifying the name to "Zhangjiang Medicine Valley+" and standardizing services [2] - Zhangjiang Medicine Valley has developed a complete ecosystem from basic research to industrial transformation, becoming a source and benchmark for China's cell therapy industry [2] Group 3 - Pudong will continue to integrate technological and industrial innovation, enhancing innovation capabilities and product carrying capacity while focusing on emerging fields such as cell gene therapy and brain-computer interfaces [3] - The goal is to establish Pudong as a global hub for biopharmaceutical innovation [3]

Group 1: Event Overview - The "Starry Pengcheng" 20+8 Industry Salon focused on the pharmaceutical and medical device sector, hosted in Shenzhen, attracted over 100 participants from various companies, investment institutions, and hospitals [2][3][12] - The event emphasized key topics such as policy empowerment, industry-finance collaboration, R&D breakthroughs, and international strategies [2] Group 2: Policy and Industry Support - Shenzhen's pharmaceutical and medical device industry is projected to reach a value of 547.83 billion yuan and 1,030 billion yuan by 2024, maintaining its leading position in China [3] - The city plans to utilize a 100 billion yuan industry fund and merger funds to support the entire value chain from R&D to mass production [3] - Policies will provide up to 60 million yuan in rewards for innovative drug development, focusing on new areas like AI+medical devices and internationalization of traditional Chinese medicine [3] Group 3: Global Trends and Local Innovations - The global biopharmaceutical market is expected to reach 445 billion USD by 2024, with North America leading in clinical trial outcomes [4] - Shenzhen ranks second in China for biopharmaceutical and medical device patents, with significant advancements in AI-assisted diagnosis and surgical robotics [4] - The local industry is encouraged to leverage domestic models to address challenges in clinical decision-making and to enhance international competitiveness [4] Group 4: Investment Insights - In 2024, over 60% of financing in Shenzhen's medical industry will focus on hard technology projects, with AI+medical sectors seeing a 30% increase in funding [5] - The investment landscape shows differentiated competition, with Beijing excelling in precision medicine and Shanghai in gene therapy, while Shenzhen benefits from its manufacturing cluster [5] Group 5: Roundtable Discussions - Experts discussed the impact of U.S.-China trade tensions on medical device exports and the importance of local R&D teams to mitigate compliance costs [7] - The rising costs of global drug development, averaging a 10% annual increase, highlight the need for AI and robotics to streamline R&D processes [7] - The market for high-end medical devices in China is expected to exceed 43 billion yuan by 2030, driven by policy incentives and clinical demand [7] Group 6: Financial Innovations - China Construction Bank's Shenzhen branch is recognized for its innovative financial services, supporting the medical industry with a comprehensive service model [10] - The bank is developing specialized credit products for medical devices and has established a platform for cross-border mergers and industry chain financing [10] Group 7: Project Showcases - The event featured presentations from innovative companies showcasing their research achievements and market strategies, fostering engagement with investment institutions [11] Group 8: Future Directions - The "Starry Pengcheng" series will continue to focus on the 20+8 industry clusters, facilitating technology commercialization and capital connections to support high-quality development in Shenzhen [12]